Congress Highlights – VJRegenMed

Highlights in the field of Treg cells from ICLE 2022

Simon Ng — Tue, 05 Apr 2022 10:25:10 +0000

Whilst the field of T-cell engineering is in its infancy, many exciting advances were presented at the International Conference on Lymphocyte Engineering (ICLE) 2022. Michael Traxlmayr, PhD, University of Natural Resources and Life Sciences, Vienna, Austria, comments on some of his highlights during the conference, including engineering Foxp3+ regulatory T (Treg) cells, which will potentially expand the utility of T-cell therapies. This interview took place at ICLE 2022.

Novel approaches in lymphocyte engineering

Simon Ng — Thu, 31 Mar 2022 14:40:57 +0000

Elvira D’Ippolito, PhD, Technical University of Munich, Munich, Germany, introduces a poster session that she is chairing at the International Conference on Lymphocyte Engineering (ICLE) 2022 on novel approaches in lymphocyte engineering. In this session, a novel avidity-controlled chimeric antigen receptor (AvidCAR) platform and a nanoparticle-sensitized photoporation approach for the safe engineering of therapeutic cells will be presented. In addition, Dr D’Ippolito describes a novel tumor model in humanized mice for the study of immunotherapy, as well as a study integrating CRISPR-cas9 screening and single-cell RNA sequencing to better understand transcriptional regulators and downstream gene networks in human regulatory T (Treg) cells. This interview took place at ICLE 2022.

Allogeneic therapy highlights at Advanced Therapies Week 2022

Simon Ng — Thu, 24 Mar 2022 13:14:37 +0000

Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, provides his highlights from Advanced Therapies Week 2022, including advances in allogeneic therapy manufacturing. He discusses developments that have led to more consistent donor material and media expansion techniques, as well as the cooperation between various companies to propel progress in the field. This interview took place at Advanced Therapies Week 2022.

Key highlights at Advanced Therapies Week 2022

Simon Ng — Mon, 28 Feb 2022 17:56:18 +0000

Nathalie Clement, PhD, Unicorn Consultations, Gainesville, FL, provides some of her highlights during Advanced Therapies Week 2022. She highlights the opportunity to network with fellow attendees and obtain their perspectives on the latest developments the field, as well as plenary sessions that focus on the achievements of the previous year within the industry. This interview took place at Advanced Therapies Week 2022.

Highlights from Advanced Therapies Week 2022

Simon Ng — Mon, 07 Feb 2022 17:06:01 +0000

Christopher Reardon, Dyno Therapeutics, Cambridge, MA, provides his highlights from Advanced Therapies Week 2022, including discussions relating to the development of fixed-bed bioreactors for adherent cell culture, which will enable the scaling-up of viral vector manufacturing. He additionally discusses improvements in the regulatory field, where authorities are streamlining the process for novel therapies, as well as improving the workplace environment for staff. This interview took place at Advanced Therapies Week 2022.

Looking forward to Advanced Therapies Week 2022

Simon Ng — Mon, 31 Jan 2022 17:59:07 +0000

Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine, Washington, D.C., shares her excitement towards meeting colleagues and learning about the latest scientific advances at the Advanced Therapies Week 2022, in particular in in vivo gene editing and in vivo chimeric antigen receptor (CAR) T-cells. This interview took place at Advanced Therapies Week 2022.

Achieving operational excellence in CGT through automation

Simon Ng — Mon, 31 Jan 2022 17:59:03 +0000

Sharon Brownlow, PhD, Cell and Gene Therapy Catapult, London, UK, discusses the challenges in achieving operational excellence in the cell and gene therapy (CGT) field and strategies to overcome these challenges. Achieving operational excellence is necessary as the timeframe to release a product is very limited, but is challenging due to the highly complex process of manufacturing CGTs. Whilst automation will have a dramatic impact in improving operational excellence, many of the systems currently used in CGT are not tailored to early product development. Dr Brownlow additionally highlights how many companies are integrating processes together and developing more configurable systems, as well as ‘factory-in-a-box’ technologies which can manufacture multiple CGTs simultaneously in a fully automated fashion. This interview took place at Advanced Therapies Week 2022.

Bioprinting highlights at TERMIS 2021

Simon Ng — Mon, 17 Jan 2022 13:05:27 +0000

Carmine Gentile, PharmD/PhD, FAHA, University of Technology Sydney, Sydney, Australia, shares his highlights in the field of bioprinting at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021). Dr Gentile describes how current innovations in biofabricating tissues have enabled lower production costs, increasing the accessibility of technologies such as 3D printing to researchers, which will ultimately drive further progress in the field. This interview took place at TERMIS 2021.

Highlights in extracellular vesicle research at TERMIS 2021

Simon Ng — Mon, 10 Jan 2022 16:16:57 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, provides her highlights from the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021) within the field of extracellular vesicles (EVs). Dr Monguió-Tortajada discusses novel research on certain EVs which are attached to the extracellular matrix (ECM), and how these particular EVs can influence the cell environment and other EVs within the cell. This interview took place at TERMIS 2021.

TERMIS 2021 highlights: Extracellular vesicles

Simon Ng — Thu, 06 Jan 2022 16:53:10 +0000

Jiao Jiao Li, PhD, University of Technology Sydney, Sydney, Australia, emphasizes the need to focus on extracellular vesicles (EVs) at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021). She highlights the potential research that will be carried out in the field of EVs, as well as the incorporation of technologies such as biosensors and artificial intelligence in the development of tissue-engineered therapies. This interview took place at TERMIS 2021.